Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 640309, 10 pages
Clinical Study

T Cell Reactivity against Mycolyl Transferase Antigen 85 of M. tuberculosis in HIV-TB Coinfected Subjects and in AIDS Patients Suffering from Tuberculosis and Nontuberculous Mycobacterial Infections

1WHO-IRTC, Department of Biochemistry, University of Lausanne, Chemin des Boveresses, 1066 Epalinges, Switzerland
2WHO/TDR, Avenue Appia 20, 1211 Geneva, Switzerland
3Hôpital Erasme, ULB, 1070 Bruxelles, Belgium
4Chest Department, Centre Hospitalier Universitaire Brugmann, Place Arthur Van Gehuchten 4, 1020 Bruxelles, Belgium
5Immunologie des Leishmanioses, Institut Pasteur de la Guyane, 97306 Cayenne, French Guiana
6Institut Guyanais de Dermatologie Tropicale, E.A. 2188, Centre hospitalier Andrée Rosemon, 97300 Cayenne, French Guiana
7Scientific Service Immunology, O.D. Communicable and Infectious Diseases, WIV-ISP-IPH Site Ukkel, 642 Engelandstraat, 1180 Brussels, Belgium

Received 2 June 2010; Accepted 16 August 2010

Academic Editor: Graeme Meintjes

Copyright © 2011 Pascal Launois et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The mycolyl transferase antigen 85 complex is a major secreted protein family from mycobacterial culture filtrate, demonstrating powerful T cell stimulatory properties in most HIV-negative, tuberculin-positive volunteers with latent M.tuberculosis infection and only weak responses in HIV-negative tuberculosis patients. Here, we have analyzed T cell reactivity against PPD and Ag85 in HIV-infected individuals, without or with clinical symptoms of tuberculosis, and in AIDS patients with disease caused by nontuberculous mycobacteria. Whereas responses to PPD were not significantly different in HIV-negative and HIV-positive tuberculin-positive volunteers, responses to Ag85 were significantly decreased in the HIV-positive (CDC-A and CDC-B) group. Tuberculosis patients demonstrated low T cell reactivity against Ag85, irrespective of HIV infection, and finally AIDS patients suffering from NTM infections were completely nonreactive to Ag85. A one-year follow-up of twelve HIV-positive tuberculin-positive individuals indicated a decreased reactivity against Ag85 in patients developing clinical tuberculosis, highlighting the protective potential of this antigen.